Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Neurocrine Biosciences, Inc (NBIX) operate in?
Neurocrine Biosciences, Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Neurocrine Biosciences, Inc (NBIX) current stock price?
As of the latest data, Neurocrine Biosciences, Inc stock price is $154.95, with a previous close of $154.23. Neurocrine Biosciences, Inc gained $0.72 in the last trading session, representing a 0.46% increase.
What is Neurocrine Biosciences, Inc (NBIX) current market capitalization?
Neurocrine Biosciences, Inc market cap is approximately 15.58 billion.
What is Neurocrine Biosciences, Inc (NBIX) Earnings Per Share (EPS)?
The trailing EPS is $6.84, and the forward EPS is $12.18.
What is Neurocrine Biosciences, Inc (NBIX) Price-to-Earnings (P/E) ratio?
Neurocrine Biosciences, Inc current P/E ratio is 22.65, with a forward P/E of 12.72.
What is Neurocrine Biosciences, Inc (NBIX) EBITDA?
Neurocrine Biosciences, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 151.50 million.
Does Neurocrine Biosciences, Inc (NBIX) pay dividends?
No. Neurocrine Biosciences, Inc does not pay a dividend.
How did Neurocrine Biosciences, Inc (NBIX) perform in its most recent earnings report?
In the last report (June 30, 2026), Neurocrine Biosciences, Inc posted an EPS surprise of 25.53% and a revenue surprise of 7.71%.
What is Neurocrine Biosciences, Inc (NBIX) beta (volatility) score?
Neurocrine Biosciences, Inc has a beta of 0.386, indicating lower volatility than the overall market.
